>
Switch to:

Cellectar Biosciences Interest Coverage

: N/A (As of Jun. 2021)
View and export this data going back to 2005. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Cellectar Biosciences's Operating Income for the three months ended in Jun. 2021 was $-6.03 Mil. Cellectar Biosciences's Interest Expense for the three months ended in Jun. 2021 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. Cellectar Biosciences Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Cellectar Biosciences's Interest Coverage or its related term are showing as below:

NAS:CLRB' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: N/A


NAS:CLRB's Interest Coverage is ranked lower than
99.99% of the 86 Companies
in the Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CLRB: N/A )

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Cellectar Biosciences Interest Coverage Historical Data

The historical data trend for Cellectar Biosciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Interest Coverage
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A No Debt N/A N/A

Cellectar Biosciences Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Interest Coverage Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison

For the Biotechnology subindustry, Cellectar Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cellectar Biosciences Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Interest Coverage falls into.



Cellectar Biosciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt.


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cellectar Biosciences's Interest Coverage for the fiscal year that ended in Dec. 2020 is calculated as

Here, for the fiscal year that ended in Dec. 2020, Cellectar Biosciences's Interest Expense was $0.00 Mil. Its Operating Income was $-15.29 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.30 Mil.

GuruFocus does not calculate Cellectar Biosciences's interest coverage with the available data.

Cellectar Biosciences's Interest Coverage for the quarter that ended in Jun. 2021 is calculated as

Here, for the three months ended in Jun. 2021, Cellectar Biosciences's Interest Expense was $0.00 Mil. Its Operating Income was $-6.03 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.24 Mil.

GuruFocus does not calculate Cellectar Biosciences's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Cellectar Biosciences  (NAS:CLRB) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Cellectar Biosciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences Business Description

Cellectar Biosciences logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.
Executives
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE COLT NECK NJ 07722
Swirsky Douglas J director C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD SUITE 455 ROCKVILLE MD 20850
Neis John director 505 S. ROSA ROAD, SUITE 201 MADISON WI 53719
Hill Stephen A director 50 AVENUE GENERAL DE GAULLE BRUXELLES C9 9999999999
Driscoll Frederick W director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DRISCOLL FREDERICK W a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Loren Stefan director 3226 AVENIDA DE SUENO CARLSBAD CA 92009
Elefant Dov officer: Chief Financial Officer EPICEPT CORPORATION 270 SYLVAN AVENUE ENGLEWOOD CLIFFS NJ 07632
Caruso James V director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC. 8383 GREENWAY BLVD STE 600 MIDDLETON WI 53562
Longcor Jarrod officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC. 300 GEORGE STREET, SUITE 301 NEW HAVEN CT 06511
Grachev Igor D officer: Chief Medical Officer 15 REID LANE MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD MALVERN PA 19355
Posner Brian M officer: Chief Financial Officer 1590 REED ROAD PENNINGTON NJ 08534
Hamill John P. officer: Interim CFO 4092 NEW HOPE ROAD FURLONG PA 18925
Kolean Chad J officer: VP, Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON WI 53716
Hertzberg Richard other: significant owner 1329 STRATFORD COURT DEL MAR CA 92014

Cellectar Biosciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)